Welcome to our dedicated page for REGENTIS BIOMATERIALS LTD. SEC filings (Ticker: RGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
Regentis Biomaterials reports that the Japan Patent Office issued a Notice of Allowance for a patent covering its organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC, its regenerative treatment for focal articular knee cartilage injuries, strengthening intellectual property protection in a key orthopedic market.
The patented technology is designed to eliminate organic solvents and deliver a stable, ready-to-use liquid, with stated manufacturing advantages including a 5x increase in yield, simplified production, improved environmental profile, and scalability. GelrinC has CE Mark approval in Europe, is over 50% enrolled in a pivotal U.S. FDA study, and targets sizable opportunities including an estimated 470,000 annual U.S. cartilage knee repair cases and a Japanese cartilage repair market projected at nearly $289 million by 2030.
Regentis Biomaterials Ltd. received approval from a European Notified Body to manufacture GelrinC using a new solvent-free process that increases production yield by approximately 400% and delivers five times more product from the same volume ahead of its European commercial launch.
The next-generation process lowers manufacturing costs, improves occupational and environmental safety, and is designed for scalable commercial production, with clinical testing validating consistent product quality and clinical performance. GelrinC is an off-the-shelf, cell-free hydrogel implant for focal knee cartilage repair, performed in a single 10-minute procedure and positioned as an alternative to microfracture and complex cell-based therapies in a U.S. market valued at $3 billion. GelrinC already holds CE Mark approval in Europe and is being introduced through Centers of Excellence and surgeon training programs, while a pivotal FDA study in the United States has completed over 50% enrollment to support potential future regulatory clearance.
Regentis Biomaterials Ltd. granted Director Susan Alpert an employee stock option for 24,826 Ordinary Shares at an exercise price of $2.16 per share. The grant, approved by the board on June 4, 2026 and subject to shareholder approval, became effective after shareholders approved it on July 9, 2026. The options vest in twelve quarterly installments starting September 4, 2026 and continue through June 4, 2029, and expire on June 4, 2036. Following this grant, Alpert holds options for 24,826 shares directly.
Regentis Biomaterials Ltd. is registering for resale by existing investors up to 3,807,143 Ordinary Shares. This includes 1,844,543 shares sold in a June 2026 private placement plus shares issuable upon exercise of Pre-Funded, Ordinary and Placement Agent Warrants. Ordinary Shares outstanding were 7,023,921 as of July 13, 2026; this is a baseline figure, not the amount being offered.
Regentis will not receive proceeds from selling shareholders’ resales. It may receive approximately $8.21 million only if all Offered Warrants are exercised for cash. Regentis is a regenerative medicine company developing GelrinC, an off-the-shelf hydrogel implant for articular knee cartilage injuries, currently in a pivotal trial in the United States and Europe.
Regentis Biomaterials director Ben-Elazar Pini received two employee stock option grants covering 8,313 and 24,826 ordinary shares. The options have exercise prices of 0.0030 and 2.1600 per share; one grant is fully vested, while the other vests quarterly through June 4, 2029 under the 2024 Share Option Plan.
Valentine Keith reported acquisition or exercise transactions in this Form 4 filing.
Regentis Biomaterials Ltd. director Keith Valentine received a grant of 24,826 employee stock options to buy ordinary shares at $2.16 per share. The grant was approved by the board on May 28, 2026, subject to shareholder approval obtained July 9, 2026. The options vest in 12 quarterly installments starting August 28, 2026 and fully vest on May 28, 2029, and expire on May 28, 2036. Following this grant, Valentine holds options for 24,826 shares from this award.
Regentis Biomaterials director Jeff Dykan reported equity compensation consisting of 24,826 employee stock options with a $2.1600 exercise price and 12,500 warrants with a $0.0030 exercise price, each for ordinary shares. The options vest quarterly over three years until fully vested on May 28, 2029, while the warrants are currently exercisable for a three-year term through February 23, 2029. Both awards were approved by the board and became effective after shareholder approval on July 9, 2026.
REGENTIS BIOMATERIALS LTD. reports that its Chief Executive Officer, Ehud Geller, received a grant of 31,250 warrants to purchase an equal number of ordinary shares at an exercise price of $0.0030 per share. These currently exercisable warrants were approved by the board on February 23, 2026, received shareholder approval on July 9, 2026, and have a three-year term expiring on February 23, 2029. Following this award, Geller holds 31,250 warrants of this series directly.
Regentis Biomaterials Ltd. granted director Efraim Cohen-Arazi an employee stock option over 24,826 underlying ordinary shares at an exercise price of 2.1600 per share. The award vests in quarterly 1/12 installments from August 28, 2026 through May 28, 2029, subject to continued employment, and relates to the 2024 Share Option Plan, which may qualify for certain Israeli Section 102 tax benefits via trustee registration.